Daniel Rivalti, Ph.D.
Patent Agent
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413

Daniel Rivalti, Ph.D.

Patent Agent

  • 901 New York Avenue, NW
  • Washington, DC 20001-4413

Daniel Rivalti, Ph.D., focuses on patent drafting and prosecution as well as strategic patent portfolio development and client counseling in the chemistry, biotechnology, and pharmaceutical fields. 

As a registered patent agent, Daniel has extensive experience in handling a wide variety of patent matters before the U.S. Patent and Trademark Office (USPTO) and in several international jurisdictions, including drafting and prosecuting patent applications; navigating reissue and post-grant proceedings; performing patentability, invalidity, and freedom-to-operate analyses; advising clients on prosecution strategies; drafting and filing provisional, utility, design, and Patent Cooperation Treaty (PCT) applications; responding to office actions; and conducting examiner interviews.

Daniel has managed matters involving a wide range of technologies, with many having complex issues concerning solid state forms (polymorphs), including pharmaceuticals, small molecule chemistry, agrochemicals, food science, polymers, and drug delivery systems.

Daniel has extensive research experience. He completed his graduate research at McGill University, after which he completed a post-doctoral fellowship at Florida State University and Virginia Commonwealth University on a research grant from the Bill & Melinda Gates Foundation. Daniel also served as a research assistant professor in the Chemical Development department at Boehringer-Ingelheim. His work has been published in numerous peer-reviewed scientific journals. 
 

Et Cetera

  • Coauthor. “Addition of non-stabilized carbon-based nucleophilic reagents to chiral N-sulfinyl imines,” Organic Reactions, 2019.
  • Coauthor. "Understanding Six-Membered NHC-Copper(I) Allylic Borylation Selectivity by Comparison with other Catalysts and Different Substrates,"Synlett, 2018.
  • Coauthor. "Computationally Assisted Mechanistic Investigation and Development of Pd-Catalyzed Asymmetric Suzuki-Miyaura and Negishi Cross-Coupling Reactions for Tetra-ortho-Substituted Biaryl Synthesis," ACS Catalysis, 2018.
  • Coauthor. "Copper-catalyzed asymmetric hydrogenation of 2-substituted ketones via dynamic kinetic resolution," Chemical Science, 2018.
  • Coauthor. "Enantioselective Synthesis of α-​(Hetero)​aryl Piperidines through Asymmetric Hydrogenation of Pyridinium Salts and Its Mechanistic Insights," Organic Letters, 2018.
  • Coauthor. "Increasing Global Access to the High-Volume HIV Drug Nevirapine Through Process Intensification," Green Chemistry, 2017.
  • Coauthor. "Effective BI-DIME Ligand for Suzuki-Miyaura Cross-Coupling Reactions in Water with 500 ppm Palladium Loading and Triton X," Asian Journal of Organic Chemistry, 2017. 
  • Coauthor. "Rh-catalyzed Asymmetric Conjugate Addition of Boronic Acids to Nitrostyrenes Employing  P-π-Hybrid Ligands," Organic Chemistry Frontiers, 2016.
  • Coauthor. "Synthesis and Reactivity Profile of Ylidenemalononitrile Enamines and Their Ester Analogs Towards Electrophiles and Nucleophiles," Journal of Organic Chemistry, 2015. 
  • Coauthor. "A Concise Total Synthesis of (R)-Puraquinonic Acid," Angewandte Chemie International Edition, 2013.

Experience

Incyte Corp. v. Concert Pharmaceuticals, Inc.

In a rare rehearing proceeding, successfully represented petitioner Incyte in an inter partes review (IPR) challenging the validity of Concert’s patent before the Patent Trial and Appeal Board (PTAB). Continued representation of appellee Incyte before the Federal Circuit and secured a unanimous affirmance of the PTAB’s obviousness determination.

IPR2017-01256, PTAB, Judges Fitzpatrick, Hulse, Yang, Smith, Franklin
19-2011, Fed. Cir., Judges Hughs, Linn, Stark

Bausch & Lomb Incorporated; Bausch & Lomb Ireland Limited; Nicox, SA v. Gland Pharma Limited, et al.

Representing Bausch & Lomb in ANDA litigation involving Vyzulta® (latanoprostene bunod) eye drops for reduction of intraocular pressure (IOP) in patients suffering from glaucoma or ocular hypertension. Bausch & Lomb sought to protect the Vyzulta® franchise against challenges asserted by generic pharmaceutical manufacturers Dr. Reddy’s and Gland. 

3:22-cv-04345, D.N.J., Judges Chesler, Kirsch, Shipp
3:23-cv-03463, D.N.J., Judge Kirsch

Concert Pharmaceuticals, Inc. v. Incyte Corp.

Successfully defended Incyte Corp. against a PGR petition related to deuterated versions of the active ingredient in Incyte’s FDA approved Jakafi® product (ruxolitinib), achieving a non-institution decision from the PTAB.

PGR2017-00034, PTAB, Judges Paulraj, Sawert, Snedden

Insights

Conference

Careers After Chemistry 2025 Careers After Chemistry 2025

September 11-12, 2025

Montreal

Virtual Seminar

Drafting Patent Applications

Drafting Patent Applications Drafting Patent Applications

February 19, 2025

Virtual

Professional Activities

  • American Chemical Society
  • Canadian Society for Chemistry
Admissions and Education

Admissions

  • U.S. Patent and Trademark Office

Education

McGill University
Ph.D., Chemistry, 2014
McGill University
B.Sc., Microbiology and Immunology, with distinction, 2006

Languages

  • French
  • Italian

Daniel's Practices

Diligence, Licensing, and Opinions
Due Diligence
Freedom to Operate Opinions
Opinions and Counseling
Prosecution and Portfolio Management
Design Rights
IP Portfolio Management
Patent Drafting and Prosecution
Patent Mining and Mapping
Patent Reissues

Daniel's Industries

Chemicals, Industrials, and Materials
Chemical
Consumer Goods and Services
Food and Beverage
Life Sciences
Biotechnology
Medical Device and Diagnostics
Pharmaceutical

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.